Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000402943
Ethics application status
Approved
Date submitted
8/04/2011
Date registered
18/04/2011
Date last updated
12/10/2017
Type of registration
Prospectively registered

Titles & IDs
Public title
Effect of Vitamin D Supplementation on Cardiovascular and Respiratory Disease Event Rates, and the incidence of fractures
Scientific title
Effect of Vitamin D Supplementation on Cardiovascular and Respiratory Disease Event Rates in Older Adults, and the incidence of non-vertebral fractures.
Secondary ID [1] 259952 0
HRC 10/400
Universal Trial Number (UTN)
U1111-1120-6224
Trial acronym
ViDA (Vitamin D Assessment) Trial
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cardiovascular Disease 265577 0
Respiratory Disease 265578 0
Non-vertebral fractures 265579 0
Cancer 305085 0
Condition category
Condition code
Cardiovascular 265722 265722 0 0
Coronary heart disease
Respiratory 265723 265723 0 0
Chronic obstructive pulmonary disease
Injuries and Accidents 265724 265724 0 0
Fractures
Cancer 304400 304400 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Vitamin D3 (cholecalciferol) 200,000 IU oral capsule at baseline, then 100,000 IU oral capsule monthly for 4 years
Intervention code [1] 264364 0
Prevention
Comparator / control treatment
Placebo capsule with sunflower lecithin
Control group
Placebo

Outcomes
Primary outcome [1] 266486 0
Incidence rate of fatal and non-fatal cardiovascular disease, as assessed by mortality, hospital discharges and family doctors.
Timepoint [1] 266486 0
4 years and 6 months after randomisation of first participant.
Secondary outcome [1] 273883 0
Incidence rate of respiratory disease, as assessed by mortality, hospital discharges and consultations with family doctors.
Timepoint [1] 273883 0
4 years and 6 months after randomisation of first participant.
Secondary outcome [2] 273884 0
Incidence rate of non-vertebral fractures, as assessed by hospital discharges, consultations with family doctors and self-reported questionnaires.
Timepoint [2] 273884 0
4 years and 6 months after randomisation of first participant.
Secondary outcome [3] 339725 0
Time to first cancer for all neoplasms: ICD-10 codes: C00-D09 (excluding non-melanoma skin cancer) reported after randomization to the NZ Cancer Registry
Timepoint [3] 339725 0
From randomization to stopping the study medication (31 July 2015)

Eligibility
Key inclusion criteria
1. age 50-84 years;
2. ability to give informed consent;
3. resident in Auckland at recruitment;
4. anticipated residence in New Zealand for the 4-year study period.
Minimum age
50 Years
Maximum age
84 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. current use of vitamin D supplements (>600 IU per day if aged 50-70 years; >800 IU per day if aged 71-84 years);
2. diagnosis of psychiatric disorders that would limit ability to comply with study protocol - ie. history of regular exacerbation of major psychosis (schizophrenia, bipolar disorder) in last 2 years
3. history of hypercalcaemia, nephrolithiasis, sarcoidosis, parathyroid disease or gastric bypass surgery;
4. enrolled in another study which could affect participation in the vitamin D study;
5. serum calcium from baseline blood sample >2.50 mmol/L.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be recruited from patient registers of general practitioners in Auckland.

Once eligibility is confirmed, randomisation to either arm of the study will be done by computer.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation with variable block size within 5 year age and ethnic strata.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
7/04/2011
Actual
3/06/2011
Date of last participant enrolment
Anticipated
Actual
23/01/2013
Date of last data collection
Anticipated
Actual
31/07/2015
Sample size
Target
5110
Accrual to date
Final
5108
Recruitment outside Australia
Country [1] 3345 0
New Zealand
State/province [1] 3345 0
Auckland

Funding & Sponsors
Funding source category [1] 264839 0
Government body
Name [1] 264839 0
Health Research Council of New Zealand
Country [1] 264839 0
New Zealand
Funding source category [2] 264840 0
Government body
Name [2] 264840 0
Accident Compensation Commission
Country [2] 264840 0
New Zealand
Primary sponsor type
University
Name
University of Auckland
Address
School of Population Health,
Tamaki Campus,
University of Auckland,
Private Bag 92019,
Auckland, 1142
Country
New Zealand
Secondary sponsor category [1] 263942 0
Individual
Name [1] 263942 0
Carlos A. Camargo, Jr, MD DrPH (Co-PI)
Address [1] 263942 0
Massachusetts General Hospital
326 Cambridge St, Suite 410
Boston
Massachusetts 02114
Country [1] 263942 0
United States of America

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 266805 0
Multi Region Ethics Committee
Ethics committee address [1] 266805 0
Ethics committee country [1] 266805 0
New Zealand
Date submitted for ethics approval [1] 266805 0
Approval date [1] 266805 0
21/10/2010
Ethics approval number [1] 266805 0
MEC/09/08/082

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 32455 0
Prof Robert Scragg
Address 32455 0
School of Population Health,
University of Auckland, Tamaki Campus,
Private Bag 92019, Auckland Mail Centre 1142,
Auckland, New Zealand
Country 32455 0
New Zealand
Phone 32455 0
+64-9-9236336
Fax 32455 0
Email 32455 0
[email protected]
Contact person for public queries
Name 15702 0
Robert Scragg
Address 15702 0
School of Population Health,
University of Auckland, Tamaki Campus,
Private Bag 92019, Auckland Mail Centre 1142,
Auckland, New Zealand
Country 15702 0
New Zealand
Phone 15702 0
+64-9-3737 599, ext 86336
Fax 15702 0
Email 15702 0
[email protected]
Contact person for scientific queries
Name 6630 0
Robert Scragg
Address 6630 0
School of Population Health,
University of Auckland, Tamaki Campus,
Private Bag 92019, Auckland Mail Centre 1142,
Auckland, New Zealand.
Country 6630 0
New Zealand
Phone 6630 0
+64-9-3737 599, ext 86336
Fax 6630 0
Email 6630 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIImpact of new vitamin D data on future studies and treatment2013https://doi.org/10.1097/mnh.0b013e3283621408
EmbaseThe Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures.2016https://dx.doi.org/10.1016/j.jsbmb.2015.09.010
EmbaseEffect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study: A randomized clinical trial.2017https://dx.doi.org/10.1001/jamacardio.2017.0175
EmbaseEffect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial.2017https://dx.doi.org/10.1016/S2213-8587%2817%2930103-1
EmbaseEffect of monthly, high-dose, long-term vitamin D supplementation on central blood pressure parameters: A randomized controlled trial substudy.2017https://dx.doi.org/10.1161/JAHA.117.006802
EmbaseA randomized, double-blind, placebo-controlled trial of the effect of monthly vitamin D supplementation in mild psoriasis*.2018https://dx.doi.org/10.1080/09546634.2017.1373735
EmbaseMonthly High-Dose Vitamin D Supplementation and Cancer Risk: A Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial.2018https://dx.doi.org/10.1001/jamaoncol.2018.2178
EmbaseMonthly high-dose Vitamin D supplementation does not increase kidney stone risk or serum calcium: Results from a randomized controlled trial.2019https://dx.doi.org/10.1093/ajcn/nqy378
EmbaseMonthly high-dose vitamin D3 supplementation and self-reported adverse events in a 4-year randomized controlled trial.2019https://dx.doi.org/10.1016/j.clnu.2018.07.034
Dimensions AIPotential Beneficial Effects of Vitamin D in Coronary Artery Disease2019https://doi.org/10.3390/nu12010099
EmbaseEffect of monthly high-dose Vitamin D supplementation on acute respiratory infections in older adults: A randomized controlled trial.2020https://dx.doi.org/10.1093/cid/ciz801
EmbaseRisk factors for reporting adverse events and for study withdrawal in a population-based trial of vitamin D supplementation.2020https://dx.doi.org/10.1016/j.jsbmb.2019.105546
EmbaseEffect of monthly vitamin D on diverticular disease hospitalization: Post-hoc analysis of a randomized controlled trial.2021https://dx.doi.org/10.1016/j.clnu.2020.08.030
EmbaseEffect of monthly vitamin D supplementation on antibiotic prescribing in older adults: A post hoc analysis of a randomized controlled trial.2021https://dx.doi.org/10.1093/ajcn/nqab015
EmbaseEffect of monthly vitamin d supplementation on preventing exacerbations of asthma or chronic obstructive pulmonary disease in older adults: Post hoc analysis of a randomized controlled trial.2021https://dx.doi.org/10.3390/nu13020521
EmbaseEffectiveness of oral vitamin D supplementation in lessening disease severity among patients with psoriasis: A systematic review and meta-analysis of randomized controlled trials.2021https://dx.doi.org/10.1016/j.nut.2020.111024
EmbaseCirculating cardiac biomarkers improve risk stratification for incident cardiovascular disease in community dwelling populations.2022https://dx.doi.org/10.1016/j.ebiom.2022.104170
EmbaseFactors associated with self-reported sun exposure in a multi-ethnic community sample from New Zealand.2022https://dx.doi.org/10.1016/j.jsbmb.2022.106131
EmbaseGenetic control of serum 25(OH)D levels and its association with ethnicity.2022https://dx.doi.org/10.1016/j.jsbmb.2022.106149
EmbaseEfficacy of vitamin D3 supplementation on cancer mortality: Systematic review and individual patient data meta-analysis of randomised controlled trials.2023https://dx.doi.org/10.1016/j.arr.2023.101923
N.B. These documents automatically identified may not have been verified by the study sponsor.